Janux Therapeutics, Inc. (NASDAQ:JANX) Position Increased by Virtu Financial LLC

Virtu Financial LLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 17.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 8,769 shares of the company’s stock after buying an additional 1,306 shares during the period. Virtu Financial LLC’s holdings in Janux Therapeutics were worth $469,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Janus Henderson Group PLC lifted its holdings in shares of Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after purchasing an additional 721,563 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in Janux Therapeutics by 190.2% in the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after buying an additional 259,445 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Janux Therapeutics by 715.0% during the fourth quarter. Victory Capital Management Inc. now owns 242,409 shares of the company’s stock valued at $12,979,000 after acquiring an additional 212,664 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in shares of Janux Therapeutics by 492.2% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 205,167 shares of the company’s stock worth $10,771,000 after acquiring an additional 170,520 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after acquiring an additional 156,675 shares during the period. Institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on JANX. Leerink Partners upped their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Stifel Nicolaus raised their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. BTIG Research boosted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Finally, Wedbush reissued an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and an average target price of $92.44.

Janux Therapeutics Stock Performance

JANX opened at $30.83 on Wednesday. The stock’s fifty day moving average is $36.33 and its 200-day moving average is $46.31. Janux Therapeutics, Inc. has a one year low of $28.92 and a one year high of $71.71. The company has a market capitalization of $1.82 billion, a PE ratio of -26.35 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 25,002 shares of company stock valued at $1,279,953. 29.40% of the stock is owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.